Moderna Inc.

MRNA | NASDAQ

Price Alert Chart Builder DCF Calculator

$182.66

+$9.72 (+5.62%)

Sep 22, 2026, 1:58 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+5.62%

(1D)

Rating

Updated: Sep 19, 2026

29.1

Fundamentals Weak

Market Sentiment Neutral

Moat Narrow

Full Analysis

Why Price Moved

1 day ago New

+12.27%

Shares are trading higher after Phase 3 melanoma d...

Key Statistics

Market Data

Market Cap $72.48B

1D Range

168.30 187.20

52W Range

22.28 187.20

Valuation (TTM)

PE -21.67

PB 10.15

EV/EBITDA -22.03

Valuation (NTM)

Forward PE N/A

Forward PEG 0.51

Price Target $115.70

Cash Flow

FCF Yield -1.8%

SBC Adj. FCF Yield -2.3%

SBC Impact -28.5%

Margins

Gross Margin -12.6%

Operating Margin -149.0%

FCF Margin -54.9%

Growth (CAGR)

Revenue 3Y | 5Y -40.5% | -19.7%

Dil EPS 3Y | 5Y 36.0% | -989.7%

FCF 3Y | 5Y 47.5% | -4900.8%

Returns

ROA -28.8%

ROE -39.2%

ROIC -39.2%

Financial Health

Net Cash

$4.5B

Current Ratio 2.29

Interest Coverage -132.80

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and deve...

Sector Healthcare

Industry Biotechnology

Employees 4,700

IPO Date Dec 6, 2018

Website www.modernatx.com

Fiscal Year January - December

Full Company Profile

Latest News

7 hours ago · 247wallst.com

Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna stock is at $181.

7 hours ago · zacks.com

MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going

Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.

1 day ago · benzinga.com

Moderna Stock Is Soaring: What's Going On?

Moderna Inc. (NASDAQ:MRNA) shares are surging Monday. The company announced three abstracts on its personalized cancer vaccine intismeran autogene were accepted for presentation at the European Society for Medical Oncology Congress.

1 day ago · 247wallst.com

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at

1 day ago · accessnewswire.com

Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event via webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT CAMBRIDGE, MA / ACCESS Newswire / September 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, which will be held October 23-27 in Madrid, Spain. The presentation details are as follows: Presidential Symposium: LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Session Type/Title: Presidential Symposium Date & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT Presenter: Georgina V.

4 days ago · fool.com

Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics is seeing significant revenue growth as its central nervous system portfolio gains commercial traction. Moderna is transitioning its mRNA platform toward a broader array of respiratory and oncology treatments to offset declining COVID-19 vaccine sales.

5 days ago · benzinga.com

Moderna Stock Is Surging: What's Going On?

Moderna Inc. (NASDAQ:MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.

5 days ago · benzinga.com

Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part

Moderna, Inc‘s (NASDAQ:MRNA) biggest problem is no longer proving that its mRNA technology can work against cancer. Investors got that answer in August.

7 days ago · zacks.com

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?

Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming one of the biggest pandemic winners, Moderna struggled with sharply lower COVID-19 vaccine demand, declining revenues and mounting losses, sending its stock tumbling from its pandemic-era highs.